Compare STWD & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | DNTH |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.9B |
| IPO Year | 2009 | 2018 |
| Metric | STWD | DNTH |
|---|---|---|
| Price | $15.67 | $106.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $20.00 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 3.6M | 544.6K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.64% | N/A |
| EPS Growth | ★ 4.55 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $1,844,289,000.00 | $2,036,000.00 |
| Revenue This Year | $283.44 | N/A |
| Revenue Next Year | $17.66 | $29.48 |
| P/E Ratio | $105.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.49 | $32.28 |
| 52 Week High | $20.62 | $117.88 |
| Indicator | STWD | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.60 | 44.50 |
| Support Level | $15.50 | $101.19 |
| Resistance Level | $16.89 | $107.99 |
| Average True Range (ATR) | 0.26 | 4.59 |
| MACD | -0.02 | -0.85 |
| Stochastic Oscillator | 10.48 | 26.26 |
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.